Search

Your search keyword '"visceral metastases"' showing total 106 results

Search Constraints

Start Over You searched for: Descriptor "visceral metastases" Remove constraint Descriptor: "visceral metastases"
106 results on '"visceral metastases"'

Search Results

1. Prognostic role of prostate specific antigen kinetics in primary high volume metastatic hormonal sensitive prostate cancer treated with novel hormonal therapy agents.

2. Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma.

Catalog

Books, media, physical & digital resources

3. Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression

4. SIGNIFICANCE OF CA15-3 IN CARCINOMA OF THE BREAST WITH VISCERAL METASTASES.

5. Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice.

6. Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases

7. Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression

8. Tumor Infiltrating Lymphocytes Predicting Long-Term Outcomes in HER2-Negative Breast Cancer Patients with Visceral Metastases.

9. Clear Cell Renal Cell Carcinoma Spinal Metastases: Which Factors Matter to the Overall Survival? A 10-Year Experience of a High-Volume Tumor Spine Center.

10. 10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice

11. Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.

12. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant

13. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.

14. Cutaneous Metastasis from Colorectal Cancer: Making Light on an Unusual and Misdiagnosed Event

15. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant.

16. Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neu receptors in breast cancer.

17. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.

18. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.

19. Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

20. Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark.

21. Cutaneous Metastasis from Colorectal Cancer: Making Light on an Unusual and Misdiagnosed Event

22. Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience

23. Impact of non-pulmonary visceral metastases in the prognosis and practice of metastatic testicular germ cell tumors.

24. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.

25. A pictorial review of the less commonly encountered patterns of metastatic prostate carcinoma

26. Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

27. Risk factors of developing visceral metastases at diagnosis in prostate cancer patients

28. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study.

29. Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs.

30. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 ...

31. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial.

33. Capecitabine and Mitomycin C Is an Effective Combination for Anthracycline- and Taxane-Resistant Metastatic Breast Cancer.

34. Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

35. Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neu receptors in breast cancer

36. Cutaneous Metastasis from Colorectal Cancer: Making Light on an Unusual and Misdiagnosed Event.

37. Efficacy of Fulvestrant in Women with Hormone-Resistant Metastatic Breast Cancer (mBC): A Canadian Province Experience †.

38. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

39. CURRENT POSSIBILITIES OF TREATMENT FOR VISCERAL METASTASES IN PATIENTS WITH METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER

40. Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases.

41. Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report

42. Impact of Non-Pulmonary Visceral Metastases in the Prognosis and Practice of Metastatic Testicular Germ Cell Tumors

44. TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk.

46. Prognostic factors for overall survival in prostate cancer patients with different site-specific visceral metastases: A study of 1358 patients.

47. Risk factors of developing visceral metastases at diagnosis in prostate cancer patients.

48. Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study

49. Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs

50. Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial